Effects in pharmaceutical interaction of Duromine with other psychostimulants
Enhancement of stimulating effect on the body occurs in Duromine interaction with other psychostimulants. Therefore, if a patient is already taking antidepressants, he should not use Duromine
Duromine promotes weight loss by suppressing appetite. Often, obese patients consider a possibility of using several drugs at once to strengthen the anorectic effect.
However, safety of Duromine rational interaction with other anorectic drugs has not been studied. Therefore, combination therapy of obesity using several stimulants is not recommended.
Patients with overweight can suffer from psychological disorders. To treat symptoms of depression and anxiety, obese patients can use:
- MAO inhibitors
- selective serotonin reuptake inhibitor (SSRI).
Concentration of MAO inhibitors increases significantly when used in conjunction with Duromine.
- This interaction leads to increased toxicity of MAO inhibitors and increases the risk of hypertensive crisis
- Moreover, MAO inhibitors reduce Duromine concentration in the blood plasma and inhibit its anorectic effect
- In simultaneous use of Duromine with such SSRI, as Paroxetine, Fluoxetine, Fluvoxamine, Sertraline and others, serotonin concentration in the body significantly increases
- Duromine interaction with these psychostimulants leads to serotonin syndrome and increases the likelihood of cardiovascular side effects.
- There is no reliable evidence that Duromine interaction with psychostimulants of SSRI group leads to valvular heart disease. However, it is recommended to avoid simultaneous use of Duromine and SSRI.